New injection for moderate-to-severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injection called GS101 compared to an existing treatment (Dupixent) for people with moderate-to-severe atopic dermatitis (eczema). If you join, you may receive either the new drug or the standard treatment, and researchers will track how well it controls your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with atopic dermatitis (eczema) for at least 1 year.
- Your eczema must be moderate to severe, meaning it covers at least 10% of your body and is rated 3 or higher on a 0-4 severity scale.
- You cannot have taken any other experimental drug or biologic within 8 weeks before starting, or within 5 half-lives of that drug.
- You cannot have received a live vaccine within 3 months before starting, or plan to during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
This study tests a new injectable medication (HXN6005) for people with moderate-to-severe eczema that hasn't been controlled by topical treatments. The goal is to see if the drug is safe and effective in reducing eczema symptoms.
This study tests a new medicine, MG-K10, given as an injection, to see if it can reduce eczema symptoms like itching and skin rash in teenagers. It's for teens whose eczema is not well controlled with topical treatments.
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
This trial tests whether an experimental medication, QL2108, works as well as a standard treatment (Dupixent) for moderate-to-severe atopic dermatitis (eczema). It may help reduce the severity of eczema symptoms and improve quality of life.
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.